和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

已收盘 12-20 16:08:10

22.150

-0.800

-3.49%

最高22.950	最低21.650	成交量699.34万
今开22.650	昨收22.950	日振幅5.66%
总市值193.15亿	流通市值193.15亿	总股本8.72亿
成交额1.54亿	换手率0.80%	流通股本8.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":22.15,"timestamp":1734682090008,"preClose":22.95,"halted":0,"volume":6993401,"delay":0,"floatShares":872000000,"shares":872000000,"eps":0.92231846,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.8,"latestTime":"12-20 16:08:10","open":22.65,"high":22.95,"low":21.65,"amount":154294616,"amplitude":0.056645,"askPrice":22.15,"askSize":83000,"bidPrice":22.1,"bidSize":83000,"shortable":3,"etf":0,"ttmEps":-0.382054711435281,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"listingDate":1624982400000,"adjPreClose":22.95,"openAndCloseTimeList":[[1734658200000,1734667200000],[1734670800000,1734681600000]],"volumeRatio":1.503483,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013/wiki","defaultTab":"wiki","newsList":[{"id":"2492456820","title":"和黄医药下跌5.01%，报21.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492456820","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492456820?lang=zh_cn&edition=full","pubTime":"2024-12-20 10:19","pubTimestamp":1734661188,"startTime":"0","endTime":"0","summary":"12月20日，和黄医药(00013)盘中下跌5.01%，截至10:19，报21.8元/股，成交3682.89万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2024年中报，和黄医药营业总收入21.79亿元、净利润1.84亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220102214ab85cc13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220102214ab85cc13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","00013","BK1587","BK1191"],"gpt_icon":0},{"id":"2492784160","title":"南向资金12月18日净卖出和黄医药303.07万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2492784160","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492784160?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:30","pubTimestamp":1734571805,"startTime":"0","endTime":"0","summary":"12月18日，南向资金减持和黄医药303.07万股连续5日减持。截止当日收盘，港股通共持有和黄医药19047.22万股，占流通股21.84%。港股通减持金额前五个股分别为美团-W、腾讯控股、药明生物、比亚迪电子、吉利汽车。和黄医药近5个交易日下跌9.96%，港股通累计减持693.85万股；近20个交易日下跌17.38%，港股通累计增持433.95万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093010ab832692&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093010ab832692&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1191","BK1588","00013","HCM"],"gpt_icon":0},{"id":"2492346130","title":"和黄医药(US ADR)下跌2.09%，报14.55美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492346130","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492346130?lang=zh_cn&edition=full","pubTime":"2024-12-19 03:04","pubTimestamp":1734548660,"startTime":"0","endTime":"0","summary":"12月19日，和黄医药(US ADR)(HCM)盘中下跌2.09%，截至03:04，报14.55美元/股，成交46.28万美元。财务数据显示，截至2024年06月30日，和黄医药(US ADR)收入总额3.06亿美元，同比减少42.64%；归母净利润2580.1万美元，同比减少84.69%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/19030446565844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4588","00013","HCM","BK1587","BK1588","BK4585","BK4531","BK1191","BK4007"],"gpt_icon":0},{"id":"2492710756","title":"南向资金12月16日净卖出和黄医药185.41万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2492710756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492710756?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:30","pubTimestamp":1734399005,"startTime":"0","endTime":"0","summary":"12月16日，南向资金减持和黄医药185.41万股连续3日减持。截止当日收盘，港股通共持有和黄医药19401.34万股，占流通股22.24%。和黄医药近5个交易日下跌12.83%，港股通累计减持258.05万股；近20个交易日下跌11.01%，港股通累计增持913.32万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093011ab7dbc6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093011ab7dbc6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","HCM","BK1588","00013","BK1191"],"gpt_icon":0},{"id":"2491596506","title":"和黄医药12月16日获主力加仓180万元 环比增加361.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491596506","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491596506?lang=zh_cn&edition=full","pubTime":"2024-12-16 16:17","pubTimestamp":1734337020,"startTime":"0","endTime":"0","summary":"12月16日, 和黄医药股价跌4.48%，报收23.45元，成交金额1.54亿元，换手率0.75%，振幅5.91%，量比1.47。和黄医药今日主力资金净流入180万元，上一交易日主力净流入39万元，今日环比增加361.54%。该股近5个交易日下跌13.38%，主力资金累计净流入1405万元；近20日主力资金累计净流入1724万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161739ab7bc9f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161739ab7bc9f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1587","00013","BK1191"],"gpt_icon":0},{"id":"2491763104","title":"和黄医药(00013)下跌5.09%，报23.3元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491763104","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491763104?lang=zh_cn&edition=full","pubTime":"2024-12-16 13:45","pubTimestamp":1734327909,"startTime":"0","endTime":"0","summary":"12月16日，和黄医药(00013)盘中下跌5.09%，截至13:45，报23.3元/股，成交6865.1万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2024年中报，和黄医药营业总收入21.79亿元、净利润1.84亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/16134546412704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4007","BK1191","BK4531","BK1588","BK4588","BK1587","00013","HCM","BK4585"],"gpt_icon":0},{"id":"2491345056","title":"和黄医药盘中异动 快速下跌5.09%报23.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491345056","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491345056?lang=zh_cn&edition=full","pubTime":"2024-12-16 13:45","pubTimestamp":1734327906,"startTime":"0","endTime":"0","summary":"2024年12月16日下午盘13时45分，和黄医药股票出现异动，股价大幅下挫5.09%。截至发稿，该股报23.300港元/股，成交量288.9万股，换手率0.33%，振幅5.09%。资金方面，该股资金流入1995.43万港元，流出3906.57万港元。和黄医药股票所在的药品行业中，整体跌幅为0.30%。其相关个股中，精优药业、中国医疗集团、海王英特龙涨幅较大，振幅较大的相关个股有精优药业、李氏大药厂、顺腾国际控股，振幅分别为29.79%、11.59%、7.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216134506ab7b79cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216134506ab7b79cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1587","00013","BK1588"],"gpt_icon":0},{"id":"2491686967","title":"和黄医药12月13日遭南向资金减持124.97万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491686967","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491686967?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:30","pubTimestamp":1734312605,"startTime":"0","endTime":"0","summary":"12月13日，南向资金减持和黄医药124.97万股。截止当日收盘，港股通共持有和黄医药19586.75万股，占流通股22.46%。和黄医药近5个交易日下跌7.88%，港股通累计减持67.84万股；近20个交易日下跌7.53%，港股通累计增持1220.20万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093017a1f1a628&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093017a1f1a628&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1588","BK1587","00013","HCM"],"gpt_icon":0},{"id":"2491364296","title":"和黄医药(00013)：继FRUZAQLA®在欧洲首次纳入医保将获得来自武田的里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2491364296","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491364296?lang=zh_cn&edition=full","pubTime":"2024-12-13 08:27","pubTimestamp":1734049650,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，该公司今日宣布将收到一笔来自合作伙伴武田 的1000万美元的里程碑付款。武田于2024年12月在西班牙取得FRUZAQLA用于治疗经治的转移性结直肠癌患者获纳入公共医疗保障范围的建议，这是在欧洲取得的首个纳入公共医疗保障范围的建议。结直肠癌是欧洲第二大癌症相关死亡原因。FRUZAQLA于2024年6月在欧盟取得欧盟委员会批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1588","BK4585","HCM","BK4007","00013","BK1191","BK4588","BK4531"],"gpt_icon":0},{"id":"2491362469","title":"和黄医药(00013.HK)将获合作伙伴1,000万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2491362469","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491362469?lang=zh_cn&edition=full","pubTime":"2024-12-13 08:23","pubTimestamp":1734049380,"startTime":"0","endTime":"0","summary":"和黄医药(00013.HK) 公布，将收到一笔来自合作伙伴武田(TAK.US)  的1,000万美元里程碑付款。武田于今年12月在西班牙取得FRUZAQLA®，用于治疗经治的转移性结直肠癌患者获纳入公共医疗保障范围的建议，这是在欧洲取得的首个纳入公共医疗保障范围的建议。公告指，FRUZAQLA®于今年6月在欧盟取得欧盟委员会批准。武田拥有在中国内地、香港和澳门以外进一步开发、商业化和生产呋喹替尼的全球独家许可。(js/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-12 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220520173826807_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220520173826807_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1403850/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1588","BK1587","00013"],"gpt_icon":0},{"id":"2490387385","title":"和黄医药(US ADR)下跌2.03%，报15.95美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490387385","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490387385?lang=zh_cn&edition=full","pubTime":"2024-12-12 22:51","pubTimestamp":1734015111,"startTime":"0","endTime":"0","summary":"12月12日，和黄医药(US ADR)(HCM)盘中下跌2.03%，截至22:51，报15.95美元/股，成交38.78万美元。财务数据显示，截至2024年06月30日，和黄医药(US ADR)收入总额3.06亿美元，同比减少42.64%；归母净利润2580.1万美元，同比减少84.69%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/12225146338207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4007","BK1588","BK4588","00013","BK1587","BK1191","BK4531","HCM","BK4585"],"gpt_icon":0},{"id":"2490879827","title":"【券商聚焦】浦银国际对2025年医药板块整体呈乐观态度 看好创新药、医疗器械及CXO","url":"https://stock-news.laohu8.com/highlight/detail?id=2490879827","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490879827?lang=zh_cn&edition=full","pubTime":"2024-12-12 15:52","pubTimestamp":1733989962,"startTime":"0","endTime":"0","summary":"2)医疗器械：看好创新高值耗材、医疗设备板块。康诺亚核心产品CM310将于2025年迎来首个完整年度商业化，作为首个国产重磅IL4R，该行认为其市场潜力巨大。此外，康诺亚研发实力强劲，NewCo形式有助于加快其出海步伐，2025年潜在出海交易有望进一步提振股票行情。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949533","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","LU2045819591.USD","LU0516422366.SGD","LU0979878070.USD","03759","09996","159938","LU0823426308.USD","BK1610","02359","BK1141","LU0417516738.SGD","09997","LU0327786744.USD","LU0348735423.USD","LU1720050803.USD","LU2328871848.SGD","01789","LU0348784397.USD","02190","02162","LU0181495838.USD","02269","159883","LU0043850808.USD","LU0307460666.USD","BK1589","SG9999014674.SGD","LU0856984785.SGD","LU0572944931.SGD","LU0819121731.USD","LU0196878994.USD","IE00B543WZ88.USD","BK1100","SG9999002463.SGD","09926","BK1191","LU2125910500.SGD","CXO","06978","BK1521","09939","LU2488822045.USD","06160","IE00B5MMRT66.SGD","02268","LU0359202008.SGD","00013","SG9999002562.SGD","06990"],"gpt_icon":1},{"id":"2490825300","title":"和黄医药(00013)宣布沃瑞沙®和泰瑞沙®的联合疗法在中国获纳入突破性治疗品种用于治疗EGFR抑制剂治疗后疾病进展的特定的肺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2490825300","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490825300?lang=zh_cn&edition=full","pubTime":"2024-12-12 12:18","pubTimestamp":1733977099,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，中国国家药品监督管理局药品审评中心将沃瑞沙和泰瑞沙纳入突破性治疗药物品种，用于治疗伴有MET扩增的接受表皮生长因子受体抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者 。获纳入突破性治疗品种的药物可在提交新药上市申请时提出附条件批准申请和优先审评审批申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和黄医药(00013)宣布沃瑞沙®和泰瑞沙®的联合疗法在中国获纳入突破性治疗品种用于治疗EGFR抑制剂治疗后疾病进展的特定的肺癌患者","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","HCM","00013","BK4585","BK4588","BK1588","BK1191","BK1587","BK4007"],"gpt_icon":0},{"id":"2490825312","title":"和黄医药(00013.HK)：沃瑞沙和泰瑞沙联合疗法获纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2490825312","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490825312?lang=zh_cn&edition=full","pubTime":"2024-12-12 12:10","pubTimestamp":1733976600,"startTime":"0","endTime":"0","summary":"和黄医药(00013.HK) 表示，国家药监局药品审评中心将沃瑞沙和泰瑞沙纳入突破性治疗药物品种，用于治疗伴有MET扩增的接受表皮生长因子受体抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者。沃瑞沙是一种强效、高选择性的口服MET酪氨酸激酶抑制剂。泰瑞沙是一种不可逆的第三代EGFR TKI。该联合疗法目前正在一项进行中的多中心、开放标签、随机对照的SACHI中国III期研究中进行评估。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-11 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220520173823854_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220520173823854_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1403649/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1587","00013","BK1588","BK1191"],"gpt_icon":0},{"id":"2490457908","title":"南向资金12月11日净买入和黄医药59.65万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2490457908","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490457908?lang=zh_cn&edition=full","pubTime":"2024-12-12 09:30","pubTimestamp":1733967006,"startTime":"0","endTime":"0","summary":"12月11日, 南向资金增持和黄医药59.65万股，连续3日增持。截止当日收盘，港股通共持有和黄医药19741.07万股，占流通股22.64%。和黄医药近5个交易日下跌4.66%，港股通累计增持15.09万股；近20个交易日下跌5.19%，港股通累计增持1558.30万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212093012ab70ff5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212093012ab70ff5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4531","00013","BK4588","BK4585","HCM"],"gpt_icon":0},{"id":"2490184571","title":"广发证券：维持和黄医药(00013)“买入”评级 合理价值41.35港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490184571","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490184571?lang=zh_cn&edition=full","pubTime":"2024-12-12 09:16","pubTimestamp":1733966186,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，广发证券发布研究报告称，维持和黄医药“买入”评级，预计24-26年归母净利润分别为0.05、0.20、0.74亿美元，通过DCF法得到公司合理价值为41.35港元/股。此次获批验证了呋喹替尼联合其他药物尤其是免疫检查点抑制剂的治疗潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013","01776"],"gpt_icon":0},{"id":"2490965723","title":"百洋医药董事长付钢：希望在First-in-Class阶段全球“抢跑”，深度布局源头创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2490965723","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490965723?lang=zh_cn&edition=full","pubTime":"2024-12-09 16:42","pubTimestamp":1733733735,"startTime":"0","endTime":"0","summary":"每经记者：金喆    每经编辑：杨夏在政策、产业、资本和产品等变量叠加的复杂环境中，能够成功应对并穿越周期的企业屈指可数。任何一家在中国有着20年历史的企业，都曾亲身经历过中国经济的风云变幻。成立于2005年的百洋医药（301015.SZ），也将迎来它的第一个20年。回想起20年前创业时的场景，百洋医药董事长付钢感触...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OJJ2nHLRD06pQeu5J6fNf6AMc6PQPsxleK7JO4VP_bAa8AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OJJ2nHLRD06pQeu5J6fNf6AMc6PQPsxleK7JO4VP_bAa8AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241209A06GFU00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241209A06GFU00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["IE00B5MMRT66.SGD","BK1587","BK1161","LU2488822045.USD","IE00BPRC5H50.USD","LU0348783233.USD","LU0417516571.SGD","IE00B543WZ88.USD","00013","09926","BK1191","BK1588","LU0348784397.USD","LU1794554557.SGD","BK1574","LU1720050803.USD"],"gpt_icon":0},{"id":"2490719420","title":"国信证券2025年医药生物策略：创新引领 产业升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2490719420","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490719420?lang=zh_cn&edition=full","pubTime":"2024-12-09 14:47","pubTimestamp":1733726829,"startTime":"0","endTime":"0","summary":"国信证券主要观点如下：需求端：医药行业需求增长稳定，且呈现需求升级的趋势。国信证券认为，展望2025年，当前国内医疗需求持续升级，宏观经济有望逐步回暖，在地缘政治扰动之下，国家有望加大对于自主可控的支持力度，建议优先配置创新药、创新器械、医疗设备等细分行业，同时建议关注AI医疗、并购重组等带来的主题投资机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926","BK1587","BK1191","IE00B5MMRT66.SGD","BK0276","BK0183","000808.SH","IE00BPRC5H50.USD","06990","00013","BK0188","LU1794554557.SGD","002736","LU0417516571.SGD","LU2488822045.USD","IE00B543WZ88.USD","BK1588","163118","LU0348784397.USD","LU0348783233.USD","BK1161","LU1720050803.USD","BK0028","BK1574","LU0196878994.USD"],"gpt_icon":0},{"id":"2489290123","title":"和黄医药首席医学官石明：出海带动明星抗癌药销量大增，目标明年实现自给自足","url":"https://stock-news.laohu8.com/highlight/detail?id=2489290123","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489290123?lang=zh_cn&edition=full","pubTime":"2024-12-07 11:13","pubTimestamp":1733541184,"startTime":"0","endTime":"0","summary":"本文来源：时代周报 作者：杜苏敏在与跨国药企武田制药就核心产品呋喹替尼达成合作后，创新药企和黄医药（00013.HK）进入快速发展期。呋喹替尼是和黄医药自主研发的首款抗癌新药，作为一款喹唑啉类小分子血管生成抑制剂，其主要作用靶点是VEGFR激酶家族（VEGFR1、2和3），用于治疗晚期结直肠癌。2018年，呋喹替尼（国内商品...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OuWmzr-TMkJ8E6SEDoKoCUkYy682mGLuSu907f-H_OO_EAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OuWmzr-TMkJ8E6SEDoKoCUkYy682mGLuSu907f-H_OO_EAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241207A031BK00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241207A031BK00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4588","HCM","BK1587","BK1191","00013","BK4531","BK1588","BK4585","BK4007"],"gpt_icon":0},{"id":"2489066403","title":"和黄医药12月06日主力资金流入40万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2489066403","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489066403?lang=zh_cn&edition=full","pubTime":"2024-12-06 16:15","pubTimestamp":1733472928,"startTime":"0","endTime":"0","summary":"12月06日, 和黄医药股价涨0.57%，报收26.65元，成交金额7948万元，换手率0.34%，振幅3.02%，量比0.65。和黄医药今日主力资金净流入40万元，连续3日净流入，上一交易日主力净流入576万元，今日环比减少93.06%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为69.23%，平均涨幅为3.80%。该股近5个交易日上涨0.38%，主力资金累计净流入1048万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流出456万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206161545a1d8a163&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206161545a1d8a163&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","00013","BK1587","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":-0.0929},{"period":"1month","weight":-0.1274},{"period":"3month","weight":-0.1563},{"period":"6month","weight":-0.1862},{"period":"1year","weight":-0.1547},{"period":"ytd","weight":-0.2003}],"compareEarnings":[{"period":"1week","weight":-0.0316},{"period":"1month","weight":0.0045},{"period":"3month","weight":0.0818},{"period":"6month","weight":0.0956},{"period":"1year","weight":0.1889},{"period":"ytd","weight":0.1587}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.130873},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058734},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.131658},{"month":4,"riseRate":0.666667,"avgChangeRate":0.04977},{"month":5,"riseRate":0,"avgChangeRate":-0.194502},{"month":6,"riseRate":0.333333,"avgChangeRate":0.018958},{"month":7,"riseRate":1,"avgChangeRate":0.135989},{"month":8,"riseRate":0.25,"avgChangeRate":-0.055482},{"month":9,"riseRate":0.5,"avgChangeRate":-0.020796},{"month":10,"riseRate":0.25,"avgChangeRate":-0.032252},{"month":11,"riseRate":0.5,"avgChangeRate":0.182346},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013062}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}